MARINUS PHARMACEUTICALS INC's ticker is MRNS and the CUSIP is 56854Q101. A total of 4 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $108,000 | +80.0% | 42,641 | +43.7% | 0.00% | – |
| Q1 2020 | $60,000 | -28.6% | 29,673 | -25.3% | 0.00% | – |
| Q4 2019 | $84,000 | +320.0% | 39,708 | +176.9% | 0.00% | – |
| Q3 2019 | $20,000 | -87.9% | 14,339 | -64.2% | 0.00% | – |
| Q2 2019 | $165,000 | -50.7% | 40,024 | -50.3% | 0.00% | – |
| Q1 2019 | $335,000 | +148.1% | 80,598 | +68.9% | 0.00% | – |
| Q4 2018 | $135,000 | -91.6% | 47,726 | -70.4% | 0.00% | – |
| Q3 2018 | $1,610,000 | +57.4% | 161,119 | +11.1% | 0.00% | – |
| Q2 2018 | $1,023,000 | -22.4% | 144,993 | -58.0% | 0.00% | -100.0% |
| Q1 2018 | $1,318,000 | -61.2% | 345,284 | -17.0% | 0.00% | -50.0% |
| Q4 2017 | $3,396,000 | +339500.0% | 416,215 | +208007.5% | 0.00% | – |
| Q3 2017 | $1,000 | – | 200 | +25.8% | 0.00% | – |
| Q2 2017 | $0 | – | 159 | -68.2% | 0.00% | – |
| Q1 2017 | $0 | -100.0% | 500 | -50.7% | 0.00% | – |
| Q4 2015 | $7,000 | +133.3% | 1,015 | +238.3% | 0.00% | – |
| Q2 2015 | $3,000 | +50.0% | 300 | +18.1% | 0.00% | – |
| Q4 2014 | $2,000 | 0.0% | 254 | -36.5% | 0.00% | – |
| Q3 2014 | $2,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 1,192,883 | $15,329,000 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 1,431,059 | $18,389,000 | 1.71% |
| Avoro Capital Advisors LLC | 3,000,000 | $38,550,000 | 0.55% |
| Palo Alto Investors LP | 31,330 | $403,000 | 0.02% |